Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F3P3U
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,965
Award facts
- Contract value 100% obligated
- $34,964.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $34,964.98, was awarded on January 8, 2026, to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pens for delivery through January 9, 2026. The award was made on a non-set-aside, competitive basis by the Defense Logistics Agency (DLA) under a firm fixed-price contract structure. The place of performance is located in Conshohocken, Pennsylvania, the company's headquarters location. This delivery order is issued under AmerisourceBergen Drug Corp's parent company Cencora, Inc.'s existing Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 31, 2031.
Dupixent is a biologic medication commonly prescribed for conditions including atopic dermatitis, asthma, and eosinophilic conditions, representing a critical therapeutic commodity within the federal military healthcare supply chain. AmerisourceBergen, through its parent Cencora, Inc., serves as a primary pharmaceutical distributor for military treatment facilities and veteran healthcare programs, supplying an extensive portfolio of brand-name and generic medications across multiple therapeutic domains. The non-set-aside competitive award status reflects the vendor's demonstrated capability to meet federal procurement requirements and maintain its role as a key medical supply chain partner for the Department of Defense healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F3P3U?
SPE2DR26F3P3U was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F3P3U worth?
The government has obligated $34,965 on SPE2DR26F3P3U.
Is contract SPE2DR26F3P3U an order under another contract?
Yes. SPE2DR26F3P3U is a delivery order under SPE2DR25D3008, an indefinite delivery contract.
Was contract SPE2DR26F3P3U competed?
The extent of competition for SPE2DR26F3P3U was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award